MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Phase 2
2–75
1 site in MN
Why this study is shown
What this study is about
This Phase 2 study is testing Cyclophosphamid in people with acute leukemia. The primary outcome being measured is Overall Survival.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, Immunological Agents (Enzyme Inhibitors), tacrolimus, treosulfan
injection, intravenous, infusion, injection (Injection)
Primary: Overall Survival
Secondary: Overall Survival
radiation
Oncology